

May 1, 2018



# **Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018**

SAN DIEGO and TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the quarter ended March 31, 2018, on Thursday, May 10, 2018 after the close of the market.

## ***Conference Call & Webcast:***

***Thursday, May 10<sup>th</sup> @ 5:00pm Eastern Time***

Toll-Free: (844) 882-7834

International: (574) 990-9707

Passcode: 2094769

Webcast: <https://edge.media-server.com/m6/p/2k9qvwez>

## ***Replays available through May 17<sup>th</sup>, 2018***

Toll-Free: (855) 859 2056

Replay Passcode: 2094769

The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at [ir.apdose.com](http://ir.apdose.com). Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended March 31, 2018 will be available on SEDAR at [www.sedar.com](http://www.sedar.com) and EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml)

## **About Aptose Biosciences**

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit [www.apdose.com](http://www.apdose.com).

For further information, please contact:

**Aptose Biosciences**

Greg Chow, CFO

647-479-9828

Email: [gchow@aptose.com](mailto:gchow@aptose.com)

**SMP Communications**

Susan Pietropaolo

201-923-2049

[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

**LifeSci Advisors**

Michael Wood

Managing Director

646-597-6983

[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)



Source: Aptose Biosciences, Inc.